Literature DB >> 17438057

Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.

Cesar A Arias1, Kavindra V Singh, Diana Panesso, Barbara E Murray.   

Abstract

Ceftobiprole (BAL9141) is an investigational cephalosporin with broad in vitro activity against gram-positive cocci, including enterococci. Ceftobiprole MICs were determined for 93 isolates of Enterococcus faecalis (including 16 beta-lactamase [Bla] producers and 17 vancomycin-resistant isolates) by an agar dilution method following the Clinical and Laboratory Standards Institute recommendations. Ceftobiprole MICs were also determined with a high inoculum concentration (10(7) CFU/ml) for a subset of five Bla producers belonging to different previously characterized clones by a broth dilution method. Time-kill and synergism studies (with either streptomycin or gentamicin) were performed with two beta-lactamase-producing isolates (TX0630 and TX5070) and two vancomycin-resistant isolates (TX2484 [VanB] and TX2784 [VanA]). The MICs of ceftobiprole for 50 and 90% of the isolates tested were 0.25 and 1 microg/ml, respectively. All Bla producers and vancomycin-resistant isolates were inhibited by concentrations of </=1 and </=4 microg/ml, respectively, at the standard inoculum concentration. Ceftobiprole MICs at a high inoculum concentration for a subset of five Bla(+) E. faecalis isolates were </=1 microg/ml. Bactericidal activity was observed against four isolates tested at concentrations as low as 1 microg/ml regardless of the production of beta-lactamase or vancomycin resistance. A combination of ceftobiprole (0.5 microg/ml) and streptomycin (25 microg/ml) was synergistic against Bla(+) TX0630 and TX5070. Ceftobiprole (0.5 microg/ml) plus gentamicin (10 microg/ml) was synergistic against VanB isolate TX2484 and showed enhanced killing, but not synergism, against TX2784 (VanA), despite the absence of high-level resistance to gentamicin. In conclusion, ceftobiprole exhibited good in vitro activity against E. faecalis, including Bla(+) and vancomycin-resistant strains, and exhibited synergism with aminoglycosides against selected isolates.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17438057      PMCID: PMC1891360          DOI: 10.1128/AAC.00131-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Michael Schleimer; Jill Sauer; Anthony Man; Norman Nashed; Thomas Brown; Antonio Perez; Erhard Weidekamm; Péter Kovács
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

2.  Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.

Authors:  R D Gonzales; P C Schreckenberger; M B Graham; S Kelkar; K DenBesten; J P Quinn
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

3.  BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis.

Authors:  J M Entenza; P Hohl; I Heinze-Krauss; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  Synergy of penicillin and gentamicin against Enterococci.

Authors:  R C Moellering; C Wennersten; A N Weinberg
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

5.  Identification of Enterococcus faecalis strains by DNA hybridization and pulsed-field gel electrophoresis.

Authors:  T M Coque; B E Murray
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

6.  Generation of restriction map of Enterococcus faecalis OG1 and investigation of growth requirements and regions encoding biosynthetic function.

Authors:  B E Murray; K V Singh; R P Ross; J D Heath; G M Dunny; G M Weinstock
Journal:  J Bacteriol       Date:  1993-08       Impact factor: 3.490

7.  Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis.

Authors:  B E Murray; B Mederski-Samaroj
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

8.  Conjugal transfer of plasmid-borne multiple antibiotic resistance in Streptococcus faecalis var. zymogenes.

Authors:  A E Jacob; S J Hobbs
Journal:  J Bacteriol       Date:  1974-02       Impact factor: 3.490

9.  Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci.

Authors:  L M Deshpande; R N Jones
Journal:  Clin Microbiol Infect       Date:  2003-11       Impact factor: 8.067

10.  Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Lars Nyman; Brigitte Roos; Michael Schleimer; Jill Sauer; Norman Nashed; Thomas Brown; Anthony Man; Erhard Weidekamm
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

View more
  14 in total

Review 1.  Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

Review 2.  Management of multidrug-resistant enterococcal infections.

Authors:  C A Arias; G A Contreras; B E Murray
Journal:  Clin Microbiol Infect       Date:  2010-06       Impact factor: 8.067

3.  Efficacy of ceftobiprole Medocaril against Enterococcus faecalis in a murine urinary tract infection model.

Authors:  Kavindra V Singh; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

Review 4.  A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.

Authors:  Maya Beganovic; Megan K Luther; Louis B Rice; Cesar A Arias; Michael J Rybak; Kerry L LaPlante
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

5.  Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.

Authors:  David J Farrell; Robert K Flamm; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

Review 6.  Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.

Authors:  Bindu Murthy; Anne Schmitt-Hoffmann
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.

Authors:  Steven N Leonard; Chrissy M Cheung; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

8.  Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium.

Authors:  Xavier Henry; Ana Amoroso; Jacques Coyette; Bernard Joris
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

9.  The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus.

Authors:  Brad Spellberg; Ashraf S Ibrahim; Michael R Yeaman; Lin Lin; Yue Fu; Valentina Avanesian; Arnold S Bayer; Scott G Filler; Peter Lipke; Henry Otoo; John E Edwards
Journal:  Infect Immun       Date:  2008-07-21       Impact factor: 3.441

Review 10.  Intrinsic and acquired resistance mechanisms in enterococcus.

Authors:  Brian L Hollenbeck; Louis B Rice
Journal:  Virulence       Date:  2012-08-15       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.